M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant

Phase 2

Completed

Conditions: CD20 Positive
Hematopoietic and Lymphoid Cell Neoplasm
Lymphocytic Neoplasm
Lymphoma

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Biological: Anti-Thymocyte Globulin
Drug: Bortezomib
Drug: Carmustine
Drug: Cytarabine
Drug: Etoposide
Biological: Filgrastim
Drug: Melphalan
Drug: Methotrexate
Biological: Rituximab
Drug: Tacrolimus

First Posted Date: 2007-02-23

Last Posted Date: 2019-09-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT00439556

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Injection Methods in Finding the Sentinel Lymph Node During Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients With Invasive Breast Cancer

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Drug: Isosulfan Blue
Procedure: Lymphangiography
Radiation: Technetium Tc 99m sulfur colloid

First Posted Date: 2007-02-22

Last Posted Date: 2012-07-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 74

Registration Number: NCT00438477

Locations: 🇺🇸
M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States

Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer

Phase 1

Completed

Conditions: Retroperitoneal Neoplasms
Gastrointestinal Neoplasms
Adenocarcinoma
Sarcoma
Ovarian Neoplasms
Peritoneal Neoplasms
Neuroblastoma
Adrenocortical Carcinoma
Wilms Tumor
Desmoplastic Small Round Cell Tumor

Interventions: Drug: CHPP of Cisplatin
Procedure: Abdominal Surgery

First Posted Date: 2007-02-19

Last Posted Date: 2012-04-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 10

Registration Number: NCT00436657

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Optical Imaging of Skin Cancers for Margin Delineation of Non-Melanoma Skin Cancers

Not Applicable

Completed

Conditions: Skin Cancer

Interventions: Procedure: Optical Imaging

First Posted Date: 2007-02-07

Last Posted Date: 2017-06-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 23

Registration Number: NCT00432471

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Proton Beam Radiation Therapy for Intraocular and Periocular Retinoblastoma

Phase 2

Terminated

Conditions: Retinoblastoma

Interventions: Radiation: Proton Beam Radiation Therapy
Procedure: Ophthalmic EUA

First Posted Date: 2007-02-07

Last Posted Date: 2015-02-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 2

Registration Number: NCT00432445

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Perifosine and Docetaxel in Patients With Relapsed Epithelial Ovarian Cancer

Phase 1

Completed

Conditions: Ovarian Cancer

Interventions: Drug: Perifosine
Drug: Docetaxel

First Posted Date: 2007-02-05

Last Posted Date: 2016-02-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 22

Registration Number: NCT00431054

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Development of the MDASI-Spine Tumor Module

Completed

Conditions: Spinal Cord Tumor

Interventions: Behavioral: Survey

First Posted Date: 2007-02-02

Last Posted Date: 2012-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 128

Registration Number: NCT00430872

Locations: 🇺🇸
U.T. M.D. Anderson Cancer Center, Houston, Texas, United States

Effects of Acupoint Electro-stimulation on Preventing Nausea and Vomiting Induced by Cisplatin or Oxaliplatin

Not Applicable

Withdrawn

Conditions: Liver Cancer
Liver Metastasis

Interventions: Procedure: Electro-Stimulation of Yongquan (K1) Acupoint

First Posted Date: 2007-02-01

Last Posted Date: 2023-03-29

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT00430313

Study of Atiprimod Treatment for Patients With Advanced Cancer

Phase 1

Terminated

Conditions: Advanced Cancer

Interventions: Drug: Atiprimod

First Posted Date: 2007-02-01

Last Posted Date: 2012-02-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 28

Registration Number: NCT00430014

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Acupuncture for Prevention of Radiation-Induced Xerostomia

Not Applicable

Completed

Conditions: Xerostomia
Nasopharyngeal Cancer
Mouth Dryness

Interventions: Other: Standard Care
Procedure: Acupuncture

First Posted Date: 2007-02-01

Last Posted Date: 2021-06-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 100

Registration Number: NCT00430378

Locations: 🇨🇳
Fudan University Cancer Hospital, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy